Trump's Chinese Import Tariff Hike Could Take Toll On Consumer Health Sector

Low margins, limited supplier alternatives leave little room for OTC drug marketers in the US to maneuver as ingredients continue  to be subject to Chinese import tariffs.  

Hand holds the magnifying glass in front of an open notebook. Among the many icons, attention is focused on the money icon. Financial operations, banking, lending, etc.

The consumer health business model leaves little room for US marketers to maneuver in light of the Trump administration's Chinese import tariffs, and OTC industry representatives are dismayed their products haven't been shielded as the tariff plan moves forward.

Active ingredients and excipients used in OTC drugs are among the items subject to an added 10% tariff when imported...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from China

More from Asia